AMD/Retina Edition: Top Headlines for Week of April 25, 2022

In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more.

Read the full coverage here:

Susvimo noninferior to monthly ranibizumab with similar efficacy

European Commission approves Beovu for DME

Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy

Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease

Choroidal vascularity index linked with geographic atrophy progression

References:

Healio Interviews

Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016.

Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle.

Press Release

Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.